PolyPeptide Group AG

As of June 30, 2026, PolyPeptide Group AG carries a market capitalization of 1.25B, placing it among publicly traded companies globally. Its enterprise value stands at 1.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PolyPeptide Group AG's next confirmed earnings release is scheduled for March 9, 2027.

As of June 30, 2026, PolyPeptide Group AG has 33.02M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PolyPeptide Group AG maintains a current ratio of 1.64, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 20, 2026, PolyPeptide Group AG's stock has gained approximately 84.88% over the past 52 weeks. The 50-day moving average sits at 30.76, while the 200-day moving average is 26.24.

As of June 30, 2026, PolyPeptide Group AG holds 54.48M in cash and equivalents against 128.36M in total debt, resulting in a net debt position of 55.85M. Total book value stands at 324.14M, with working capital of 125.75M providing operational flexibility.